Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
Release Notes Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
ALL
MCID: LKM062
MIFTS: 69

Leukemia, Acute Lymphoblastic (ALL)

Categories: Blood diseases, Cancer diseases, Genetic diseases, Immune diseases, Rare diseases
Data Licensing
For inquiries, contact:
[email protected]
Genes Variations Tissues Related diseases Publications Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Leukemia, Acute Lymphoblastic

About this section

MalaCards integrated aliases for Leukemia, Acute Lymphoblastic:

Name: Leukemia, Acute Lymphoblastic 57 73 36
Acute Lymphoblastic Leukemia 11 19 58 75 5 14 16
Acute Lymphocytic Leukemia 19 58 75 41 71
All 57 11 19 58 73
Leukemia, Acute Lymphocytic, Susceptibility to, 1 57 12
Leukemia, Acute Lymphoblastic, Susceptibility to 28 5
Precursor Lymphoblastic Lymphoma/leukemia 11 16
B-Cell Acute Lymphoblastic Leukemia 28 16
Acute Lymphoblastic Leukaemia 11 14
Precursor Lymphoid Neoplasm 58 71
Leukemia, Acute Lymphoblastic, Susceptibility to, 3 71
Precursor Cell Lymphoblastic Leukemia Lymphoma 71
Leukemia Acute Lymphoblastic B-Hyperdiploid 73
Childhood Acute Lymphoblastic Leukemia 73
Acute Lymphoblastic Leukemia/lymphoma 58
Leukemia B-Cell Acute Lymphoblastic 73
Leukemia T-Cell Acute Lymphoblastic 73
Leukemia, Acute Lymphoblastic, 3 73
Leukemia, Lymphocytic, Acute, L1 71
Leukemia Acute Lymphoblastic 1 73
Leukemia, Acute, Lymphoblastic 38
Leukemia, Acute Lymphocytic 1 57
Leukemia Acute Lymphocytic 1 73
Lymphoblastic Leukemia Acute 53
Acute Lymphocytic Leukaemia 11
Leukemia Acute Lymphocytic 73
All3 73
All1 73

Characteristics:


Prevelance:

Acute Lymphoblastic Leukemia: 1-9/100000 (France, United States) 1-5/10000 (United States, Europe) 58

Age Of Onset:

Acute Lymphoblastic Leukemia: All ages 58

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases Genetic diseases
Anatomical: Blood diseases Immune diseases
See all MalaCards categories (disease lists)
ICD10: 31 32
ICD11: 33
Orphanet: 58  
Rare haematological diseases


External Ids:

Disease Ontology 11 DOID:9952
OMIM® 57 613065
ICD9CM 34 204.0
MeSH 43 D054198
NCIt 49 C3167 C7055
SNOMED-CT 68 128822004
ICD10 31 C91.0
ICD10 via Orphanet 32 C91.0
UMLS via Orphanet 72 C0023449
Orphanet 58 ORPHA513
SNOMED-CT via HPO 69 91857003
UMLS 71 C0023449 C0023452 C1335469 more
Sources

Summaries for Leukemia, Acute Lymphoblastic

About this section

MedlinePlus: 41 What is leukemia? Leukemia is a term for cancers of the blood cells. Leukemia starts in blood-forming tissues such as the bone marrow. Your bone marrow makes the cells which will develop into white blood cells, red blood cells, and platelets. Each type of cell has a different job: White blood cells help your body fight infection Red blood cells deliver oxygen from your lungs to your tissues and organs Platelets help form clots to stop bleeding When you have leukemia, your bone marrow makes large numbers of abnormal cells. This problem most often happens with white blood cells. These abnormal cells build up in your bone marrow and blood. They crowd out the healthy blood cells and make it hard for your cells and blood to do their work. What is acute lymphocytic leukemia (ALL)? Acute lymphocytic leukemia is a type of acute leukemia. It's also called ALL and acute lymphoblastic leukemia. "Acute" means that it usually gets worse quickly if it's not treated. ALL is the most common type of cancer in children. It can also affect adults. In ALL, the bone marrow makes too many lymphocytes, a type of white blood cell. These cells normally help your body fight infection. But in ALL, they are abnormal and cannot fight infection very well. They also crowd out the healthy cells, which can lead to infection, anemia, and easy bleeding. These abnormal cells can also spread to other parts of the body, including the brain and spinal cord. What causes acute lymphocytic leukemia (ALL)? ALL happens when there are changes in the genetic material (DNA) in bone marrow cells. The cause of these genetic changes is unknown. However, there are certain factors that raise your risk of ALL. Who is at risk for acute lymphocytic leukemia (ALL)? The factors that raise your risk of ALL include: Being male Being white Being over age 70 Having had chemotherapy or radiation therapy Having been exposed to high levels of radiation Having certain genetic disorders, such as Down syndrome What are the symptoms of acute lymphocytic leukemia (ALL)? The signs and symptoms of ALL include: Weakness or feeling tired Fever or night sweats Easy bruising or bleeding Petechiae, which are tiny red dots under the skin. They are caused by bleeding. Shortness of breath Weight loss or loss of appetite Pain in the bones or stomach Pain or feeling of fullness below the ribs Swollen lymph nodes - you may notice them as painless lumps in the neck, underarm, stomach, or groin Having had many infections How is acute lymphocytic leukemia (ALL) diagnosed? Your health care provider may use many tools to diagnose ALL and figure out which subtype you have: A physical exam A medical history Blood tests, such as Complete blood count (CBC) with differential Blood chemistry tests such as a basic metabolic panel (BMP), comprehensive metabolic panel (CMP), kidney function tests, liver function tests, and electrolyte panel Blood smear Bone marrow tests. There are two main types - bone marrow aspiration and bone marrow biopsy. Both tests involve removing a sample of bone marrow and bone. The samples are sent to a lab for testing. Genetic tests to look for gene and chromosome changes If you are diagnosed with ALL, you may have additional tests to see whether the cancer has spread. These include imaging tests and a lumbar puncture, which is a procedure to collect and test cerebrospinal fluid (CSF). What are the treatments for acute lymphocytic leukemia (ALL)? Treatments for ALL include: Chemotherapy Radiation therapy Chemotherapy with stem cell transplant Targeted therapy, which uses drugs or other substances that attack specific cancer cells with less harm to normal cells Treatment is usually done in two phases: The goal of the first phase is to kill the leukemia cells in the blood and bone marrow. This treatment puts the leukemia into remission. Remission means that the signs and symptoms of cancer are reduced or have disappeared. The second phase is known as post-remission therapy. Its goal is to prevent a relapse (return) of the cancer. It involves killing any remaining leukemia cells that may not be active but could begin to regrow. Treatment during both phases also usually includes central nervous system (CNS) prophylaxis therapy. This therapy helps prevent the spread of leukemia cells to the brain and spinal cord. It may be high dose chemotherapy or chemotherapy injected into the spinal cord. It also sometimes includes radiation therapy. NIH: National Cancer Institute

MalaCards based summary: Leukemia, Acute Lymphoblastic, also known as acute lymphoblastic leukemia, is related to childhood b-cell acute lymphoblastic leukemia and b-lymphoblastic leukemia/lymphoma, and has symptoms including angina pectoris, chest pain and bone pain. An important gene associated with Leukemia, Acute Lymphoblastic is PAX5 (Paired Box 5), and among its related pathways/superpathways are Cell differentiation - expanded index and miRNAs involvement in the immune response in sepsis. The drugs Sargramostim and Epirubicin have been mentioned in the context of this disorder. Affiliated tissues include Blood, and related phenotype is acute lymphoblastic leukemia.

UniProtKB/Swiss-Prot 73 Leukemia, acute lymphoblastic: A subtype of acute leukemia, a cancer of the white blood cells. ALL is a malignant disease of bone marrow and the most common malignancy diagnosed in children. The malignant cells are lymphoid precursor cells (lymphoblasts) that are arrested in an early stage of development. The lymphoblasts replace the normal marrow elements, resulting in a marked decrease in the production of normal blood cells. Consequently, anemia, thrombocytopenia, and neutropenia occur to varying degrees. The lymphoblasts also proliferate in organs other than the marrow, particularly the liver, spleen, and lymphnodes.

Leukemia, acute lymphoblastic, 3: A subtype of acute leukemia, a cancer of the white blood cells. Acute lymphoblastic anemia is a malignant disease of bone marrow and the most common malignancy diagnosed in children. The malignant cells are lymphoid precursor cells (lymphoblasts) that are arrested in an early stage of development. The lymphoblasts replace the normal marrow elements, resulting in a marked decrease in the production of normal blood cells. Consequently, anemia, thrombocytopenia, and neutropenia occur to varying degrees. The lymphoblasts also proliferate in organs other than the marrow, particularly the liver, spleen, and lymphnodes.

GARD: 19 Acute lymphoblastic leukemia (ALL) is a type of cancer in which the bone marrow makes too many lymphocytes (a type of white blood cell). It may develop in children or adults. ALL spreads to the blood and then may spread to other areas of the body such as the lymph nodes, liver, spleen, central nervous system, and testicles (in males). Signs and symptoms of ALL may include fever, easy bruising or bleeding, feeling tired, loss of appetite, pain in the bones or abdomen, and painless lumps in the neck, underarm, stomach, or groin. ALL is typically caused by random, non-inherited changes in the DNA of immature lymphocytes called lymphoblasts. However, some people may inherit a genetic susceptibility to developing ALL. The risk to develop ALL may also be increased by past treatment for cancer and by having certain genetic conditions or syndromes. Having one or more risk factors does not mean that a person definitely will develop ALL.

OMIM®: 57 Acute lymphoblastic leukemia (ALL), also known as acute lymphocytic leukemia, is a subtype of acute leukemia, a cancer of the white blood cells. Somatically acquired mutations in several genes have been identified in ALL lymphoblasts, cells in the early stages of differentiation. Germline variation in certain genes may also predispose to susceptibility to ALL (Trevino et al., 2009). (613065) (Updated 08-Dec-2022)

Orphanet: 58 A rare disease characterized by malignant proliferation of lymphoid cells blocked at an early stage of differentiation and accounts for 75% of all cases of childhood leukaemia.

Disease Ontology: 11 A acute leukemia that is characterized by over production of lymphoblasts.

Wikipedia: 75 Acute lymphoblastic leukemia (ALL) is a cancer of the lymphoid line of blood cells characterized by the... more...
Sources

Related Diseases for Leukemia, Acute Lymphoblastic

About this section

Diseases in the Leukemia, Acute Lymphoblastic family:

Leukemia, Acute Lymphoblastic 2 Leukemia, Acute Lymphoblastic 3

Diseases related to Leukemia, Acute Lymphoblastic via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1725)
# Related Disease Score Top Affiliating Genes
1 childhood b-cell acute lymphoblastic leukemia 33.4 PAX5 ETV6
2 b-lymphoblastic leukemia/lymphoma 32.6 PAX5 FLT3 ETV6
3 hematologic cancer 32.5 XIST PAX5 MIR335 MIR27A MIR223 MIR21
4 childhood leukemia 32.5 MIR335 FLT3 ETV6
5 t-cell acute lymphoblastic leukemia 32.4 NALT1 MIR27A MIR223 MIR155
6 myeloma, multiple 32.1 PAX5 MIR335 MIR27A MIR21 MIR155 MIR125A
7 lymphoma, non-hodgkin, familial 32.0 PAX5 NBN MIR335 MIR27A MIR223 MIR21
8 nervous system disease 32.0 MIR335 MIR27A MIR223 MIR21 MIR155 MIR152
9 leukemia, chronic lymphocytic 31.9 PAX5 MIR27A MIR223 MIR21 MIR155 MIR125A
10 central nervous system disease 31.9 MIR335 MIR27A MIR223 MIR21 MIR155 MIR125A
11 immune deficiency disease 31.8 NBN MIR27A MIR223 MIR21 MIR155 MIR125A
12 lymphatic system disease 31.8 MIR335 MIR27A MIR223 MIR21 MIR155 MIR125A
13 leukemia, chronic myeloid 31.8 MIR223 MIR203A MIR155 MIR125A FLT3 ETV6
14 body mass index quantitative trait locus 11 31.8 MIR335 MIR27A MIR223 MIR21 MIR155 MIR125A
15 central nervous system cancer 31.6 MIR335 MIR27A MIR223 MIR21 MIR155 MIR125A
16 leukemia, acute myeloid 31.5 PAX5 MIR335 MIR27A MIR223 MIR21 MIR155
17 type 2 diabetes mellitus 31.5 MIR335 MIR27A MIR223 MIR21 MIR155 MIR125A
18 cardiovascular system disease 31.5 MIR335 MIR27A MIR223 MIR21 MIR155 MIR125A
19 acute biphenotypic leukemia 31.4 PAX5 FLT3 ETV6
20 hepatocellular carcinoma 31.4 XIST NBN MIR335 MIR27A MIR223 MIR21
21 gastrointestinal system disease 31.3 MIR335 MIR27A MIR223 MIR21 MIR155 MIR125A
22 bone disease 31.3 MIR27A MIR223 MIR21 MIR155 MIR125A
23 b-lymphoblastic leukemia/lymphoma with iamp21 31.3 PAX5 ETV6
24 bone marrow cancer 31.3 MIR335 MIR27A MIR21 MIR155 MIR125A FLT3
25 bone inflammation disease 31.3 MIR335 MIR27A MIR223 MIR21 MIR155 MIR125A
26 retinitis pigmentosa 11 31.3 XIST MIR335 MIR125A CDKN2B-AS1
27 peripheral t-cell lymphoma 31.3 PAX5 MIR21 MIR155 ETV6
28 high grade glioma 31.3 XIST MIR21 MIR155 CDKN2B-AS1
29 cerebrovascular disease 31.2 MIR335 MIR27A MIR223 MIR21 MIR155 MIR125A
30 skin disease 31.2 MIR27A MIR223 MIR21 MIR203A MIR155 MIR125A
31 nasopharyngeal carcinoma 31.2 XIST MIR335 MIR223 MIR21 MIR155 MIR152
32 lipoprotein quantitative trait locus 31.1 MIR27A MIR223 MIR21 MIR155 MIR125A CDKN2B-AS1
33 overnutrition 31.1 MIR27A MIR223 MIR21 MIR155 MIR125A
34 oral squamous cell carcinoma 31.1 MIR27A MIR223 MIR21 MIR203A MIR155 MIR152
35 disease of mental health 31.1 MIR335 MIR27A MIR223 MIR21 MIR155 MIR125A
36 inherited metabolic disorder 31.1 MIR335 MIR27A MIR223 MIR21 MIR155 MIR125A
37 malignant astrocytoma 31.1 MIR335 MIR27A MIR223 MIR21 MIR155 MIR125A
38 esophageal cancer 31.1 MIR27A MIR223 MIR21 MIR203A MIR125A CDKN2B-AS1
39 connective tissue disease 31.1 MIR335 MIR27A MIR223 MIR21 MIR155 MIR152
40 retinal vascular disease 31.1 MIR335 MIR27A MIR223 MIR21
41 ovarian cancer 31.1 XIST NBN MIR335 MIR27A MIR223 MIR21
42 stomach disease 31.1 MIR335 MIR27A MIR223 MIR21 MIR155 MIR125A
43 alzheimer disease, familial, 1 31.0 RTN4R MIR335 MIR27A MIR223 MIR21 MIR125A
44 diffuse large b-cell lymphoma 31.0 PAX5 MIR21 MIR155 MIR125A
45 renal cell carcinoma, nonpapillary 31.0 MIR335 MIR27A MIR223 MIR21 MIR155 MIR125A
46 periodontitis 31.0 MIR21 MIR125A CDKN2B-AS1
47 myelofibrosis 31.0 MIR223 FLT3 ETV6 CDKN2B-AS1
48 eye disease 31.0 MIR335 MIR27A MIR223 MIR21 MIR155 MIR125A
49 dermatomyositis 30.9 MIR335 MIR223 MIR21 MIR155
50 acute myelomonocytic leukemia 30.9 FLT3 ETV6

Graphical network of the top 20 diseases related to Leukemia, Acute Lymphoblastic:



Diseases related to Leukemia, Acute Lymphoblastic
Sources

Symptoms & Phenotypes for Leukemia, Acute Lymphoblastic

About this section

Human phenotypes related to Leukemia, Acute Lymphoblastic:

30
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 acute lymphoblastic leukemia 30 HP:0006721

Clinical features from OMIM®:

613065 (Updated 08-Dec-2022)

UMLS symptoms related to Leukemia, Acute Lymphoblastic:


angina pectoris; chest pain; bone pain; edema
Sources

Drugs & Therapeutics for Leukemia, Acute Lymphoblastic

About this section

Drugs for Leukemia, Acute Lymphoblastic (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 521)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Sargramostim Approved, Investigational Phase 4 123774-72-1
2
Epirubicin Approved Phase 4 56420-45-2 41867
3
Morphine Approved, Investigational Phase 4 57-27-2 5288826
4
Nicotine Approved Phase 4 54-11-5 942 89594
5
Cladribine Approved, Investigational Phase 4 4291-63-8 20279
6
Teniposide Approved Phase 4 29767-20-2 34698 452548
7
Oprelvekin Approved, Investigational Phase 4 145941-26-0
8
Micafungin Approved, Investigational Phase 4 235114-32-6 477468
9
Treosulfan Approved, Investigational Phase 4 299-75-2 9296
10
Simvastatin Approved Phase 4 79902-63-9 54454
11
Atomoxetine Approved Phase 4 82248-59-7, 83015-26-3 54841
12
Acetylcysteine Approved, Investigational Phase 4 616-91-1 581 12035
13
Cholecalciferol Approved, Nutraceutical, Vet_approved Phase 4 67-97-0, 1406-16-2 5280795 10883523
14
Calcifediol Approved, Nutraceutical Phase 4 19356-17-3 5283731
15
Ergocalciferol Approved, Nutraceutical Phase 4 50-14-6 5280793
16
Molgramostim Investigational Phase 4 99283-10-0
17 Thymoglobulin Phase 4
18 Adjuvants, Immunologic Phase 4
19
Ethylene Phase 4 74-85-1 6325
20 Antiprotozoal Agents Phase 4
21 Antiparasitic Agents Phase 4
22 Calciferol Phase 4
23 Heptavalent Pneumococcal Conjugate Vaccine Phase 4
24
Vitamin D2 Phase 4 3249
25 Ergocalciferols Phase 4
26 Hydroxycholecalciferols Phase 4
27 HH-GV-678 Phase 4
28 Antidotes Phase 4
29 Antioxidants Phase 4
30 Protective Agents Phase 4
31 Neurotransmitter Agents Phase 4
32 Respiratory System Agents Phase 4
33 Adrenergic Agents Phase 4
34 Expectorants Phase 4
35 N-monoacetylcystine Phase 4
36
Pentoxifylline Approved, Investigational Phase 2, Phase 3 6493-05-6 4740
37
Lorazepam Approved Phase 3 846-49-1 3958
38
Sirolimus Approved, Investigational Phase 3 53123-88-9 5284616 6436030
39
Benzocaine Approved, Investigational Phase 3 1994-09-7, 94-09-7 2337
40
Tannic acid Approved Phase 3 1401-55-4 16129878 16129778
41
Adenosine Approved, Investigational Phase 3 58-61-7 60961
42
Pentostatin Approved, Investigational Phase 3 53910-25-1 439693
43
Rasburicase Approved, Investigational Phase 3 134774-45-1
44
Calcium carbonate Approved, Investigational Phase 3 471-34-1
45
Cobalt Approved, Experimental, Withdrawn Phase 3 7440-48-4 104729
46
Dactinomycin Approved, Investigational Phase 3 50-76-0 2019 457193
47
Apixaban Approved Phase 3 503612-47-3 10182969
48
Erythromycin Approved, Investigational, Vet_approved Phase 2, Phase 3 114-07-8 12560
49
Chlorhexidine Approved, Vet_approved, Withdrawn Phase 3 55-56-1 2713 9552079
50
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096

Interventional clinical trials:

(show top 50) (show all 1760)
# Name Status NCT ID Phase Drugs
1 Philadelphia -Negative High-risk Children Acute Lymphoblastic Leukemia(ALL) Treatment:Induction Therapy:Vincristine(V),Idarubicin(I),L-asparaginase(L),Dexamethasone(D);Consolidation:V+Daunorubicin(D)+L+D, Methotrexate,Cytarabine Unknown status NCT01990807 Phase 4 Idarubicin(IDA)
2 An Open-label,Multi-center,Prospective Study of Idarubicin and Etoposide Intensified Conditioning Regimen Allogeneic Hematopoietic Stem Cell Transplantation for Adult Acute Lymphoblastic Leukemia Unknown status NCT01873807 Phase 4 IDA;CTX;VP-16
3 The Combination of Lower Dosage of Chemotherapy With Tyrosine Kinase Inhibitor to Treat Newly Diagnosed ph+ Acute Lymphoblastic Leukemia Patients Unknown status NCT02690922 Phase 4 Dasatinib;prednisone;dexamethasone;methotrexate
4 Plasma Kinetics of Tablet and Liquid Formulations of 6-mercaptopurine in Childhood Acute Lymphoblastic Leukemia. Unknown status NCT01906671 Phase 4 Xaluprine;Puri-Nethol
5 Clinical Study of GD-2008 ALL Protocol for Childhood Acute Lymphoblastic Leukemia in Guangdong Province Unknown status NCT00846703 Phase 4 6-mercaptopurine, Methotrexate;6-mercaptopurine, Methotrexate, Vincristine, Dexamethasone
6 PEG-asparaginase During Two Treatment Courses in the Treatment of Childhood Acute Lymphoblastic Leukemia Unknown status NCT00192673 Phase 4 PEG-asparaginase
7 Multicenter Study To Optimize Treatment in Elderly Patients (> 55 Years, No Upper Age Limit) With Acute Lymphoblastic Leukemia (GMALL Elderly 1/2003)(Amend 2) Unknown status NCT00198978 Phase 4 Cyclophosphamide;Dexamethasone / Prednisolone;Cytarabine;Idarubicin;Granulocyte-Colony-Stimulating Factor;Mercaptopurine;Methotrexate;Rituximab;HDARAC;Vincristine;Depocyte;Asparaginase
8 Determinants of Mercaptopurine Toxicity in Paediatric Acute Lymphoblastic Unknown status NCT03920813 Phase 4 Mercaptopurine
9 Intensification Therapy of Mature B-ALL, Burkitt and Burkitt Like and Other High Grade Non-Hodgkin's Lymphoma in Adults Unknown status NCT00797810 Phase 4 Rituximab
10 Medical Research Council Working Party on Leukaemia in Children UK National Acute Lymphoblastic Leukaemia (ALL) Trial: UKALL 2003 Unknown status NCT00222612 Phase 4 Standard childhood UK ALL protocol;Intensified treatment including Capizzi maintenance
11 Ma-Spore ALL 2010 Study Unknown status NCT02894645 Phase 4 Prednisolone;Dexamethasone;L-Asparaginase;Vincristine;Methotrexate;Daunorubicin;Doxorubicin;Cyclophosphamide;Cytarabine;6-Mercaptopurine;Thioguanine;Fludarabine;Imatinib
12 A Clinical Trial of Decitabine Combined With CODOX-M/IVAC in Relapsed or Refractory T-lymphoblastic Lymphoma Unknown status NCT03558412 Phase 4 Decitabine
13 Hematology , Shanghai Jiaotong University Affiliated Shanghai First People's Hospital, Shanghai, China Unknown status NCT02938741 Phase 4 Anti-human Thymoglobulin;Placebo
14 G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant Tumor: a Prospective, Multicentre, Randomised Controlled Trial Unknown status NCT02933333 Phase 4
15 LAL-Ph-2000: Treatment of Acute Lymphoblastic Leukemia Chromosome Philadelphia Positive Completed NCT00526305 Phase 4 Vincristine;Daunorubicin;Prednisone;L-Asparaginase;Mitoxantrone;Cytosine Arabinoside;Hydrocortisone;Mercaptopurine;Cyclophosphamide;Dexamethasone
16 Pulses of Vincristine and Dexamethasone During Maintenance in BFM Protocols for Children With Intermediate-Risk Acute Lymphoblastic Leukemia Completed NCT00411541 Phase 4 vincristine;dexamethasone
17 PETHEMA LAL-RI/96: Treatment for Patients With Standard Risk Acute Lymphoblastic Leukemia Completed NCT00494897 Phase 4 Asparaginase;Cyclophosphamide;Cytarabine;Daunorubicin;Mercaptopurine;Prednisone;Vincristine;Methotrexate
18 LAL-AR-N-2005: Study Treatment for Children High Risk Acute Lymphoblastic Leukemia Completed NCT00526409 Phase 4 Prednisolone;Daunorubicin;Vincristine;L-Asparaginase;Cyclophosphamide;Methotrexate;Cytosine Arabinoside
19 Treatment of High Risk Adult Acute Lymphoblastic Leukemia Completed NCT00853008 Phase 4 Vincristine;Daunorubicin;Prednisone;Mitoxantrone;Cytosine Arabinoside;Dexamethasone;Methotrexate (MTX);Cytarabine;ASP;Mercaptopurine;Teniposide;Hydrocortisone
20 ALL-REZ BFM 2002: Protocol for the Treatment of Children With Relapsed Acute Lymphoblastic Leukemia Completed NCT00114348 Phase 4
21 Vaccinating Children After Chemotherapy for Acute Lymphoblastic Leukemia: A Canadian Immunization Research Network Study Completed NCT02447718 Phase 4
22 German Multicenter Trial for Treatment Optimisation in Acute Lymphoblastic Leukemia in Adults and Adolescents Above 15 Years With Rituximab for Improvement of Prognosis in CD20 Positive Standard Risk ALL (Amend 2) Completed NCT00199004 Phase 4 Cyclophosphamide;Dexamethasone / Prednisolone;Vincristine;Daunorubicin;Asparaginase;Methotrexate;Cytarabine;Mercaptopurine;G-CSF;Vindesine;VP16;Adriamycin;Thioguanine;VM26;Rituximab
23 Pilot Study for Treatment of Elderly Patients (>65 Years) With Acute Lymphoblastic Leukemia Completed NCT00199095 Phase 4 Adriamycin;Cyclophosphamide;Cytarabine;Dexamethasone;Idarubicin;Ifosfamide;Methotrexate;Mercaptopurine;VM26;Vincristine
24 Multicenter Trial for Treatment of Acute Lymphoblastic Leukemia in Adults (05/93) Completed NCT00199069 Phase 4 Asparaginase;Vincristine;Daunorubicin, Adriamycin;Cyclophosphamide;Ifosfamide;Cytarabine;Mitoxantrone;Methotrexate;6-Mercaptopurine;6-Thioguanine;VM26;Dexamethasone / Prednisolone
25 German Multicenter Study for Treatment Optimisation in Acute Lymphoblastic Leukemia in Adults and Adolescents Above 15 Years (Amend 3) (GMALL 07/2003) Completed NCT00198991 Phase 4 Cyclophosphamide;Dexamethasone;Vincristine;Daunorubicin;Asparaginase;Methotrexate;Cytarabine;Mercaptopurine;G-CSF;Vindesine;Etoposide;Prednisolone;Adriamycin;Thioguanine;Teniposide;Idarubicin;Fludarabine;Cladribine
26 Effect of Treatment Using rhIL-11 in Patients With Thrombocytopenia After Chemotherapy for Childhood Acute Lymphoblastic Leukemia Completed NCT02314273 Phase 4 rhIL-11
27 Prospective Study of Rituximab Combined With Chemotherapy for CD20+ Adult Acute Lymphoblastic Leukemia Completed NCT01358253 Phase 4 Cyclophosphamide;Doxorubicin;Vincristine;Dexamethasone;Cytarabine;Methotrexate;Rituximab;6-Mercaptopurine;Prednisone;L-asparaginase
28 LAL-BR/2001: Study Treatment to Low Risk ALL Completed NCT00526175 Phase 4 Prednisone;Vincristine;Daunorubicin;L-Asparaginase;Cyclophosphamide;Methotrexate;Cytosine Arabinoside;Mercaptopurine;VP-16
29 Learning Impairments Among Survivors of Childhood Cancer Completed NCT00576472 Phase 4 Methylphenidate
30 Multicenter Trial for Treatment of Acute Lymphocytic Leukemia in Adults (Pilot Study 06/99) Completed NCT00199056 Phase 4 Dexamethasone / Prednisolone;Cyclophosphamide;Methotrexate;Vincristine / Vindesine;Daunorubicin;Asparaginase;G-CSF;Cytarabine;6-Mercaptopurine;VP16;Adriamycin;Thioguanine;VM26;Idarubicin;Fludarabine;Ifosfamide
31 A Randomized Open-Label Trial of Posaconazole Versus Micafungin for Prophylaxis Against Invasive Fungal Infections During Neutropenia in Patients Undergoing Chemotherapy for Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia or Myelodysplastic Syndrome Completed NCT01200355 Phase 4 micafungin;posaconazole
32 The Study on the Pharmacokinetics of Pegylated Recombinant Human Granulocyte Stimulating Factor（PEG-rhG-CSF） in Children and Adolescents Completed NCT02953730 Phase 4 PEG-rhG-CSF
33 A Randomized Phase IV Control Trial of Single High Dose Oral Vitamin D3 (Stoss Therapy) in Pediatric Patients Undergoing HSCT to Prevent Vitamin D Deficiency and Insufficiency During Transplant Completed NCT03176849 Phase 4
34 Multicenter Trial for Treatment Optimization in T-lymphoblastic Lymphoma in Adults and Adolescents Older Than 15 Years (GMALL T-LBL 1/2004) (Amend 1) Completed NCT00199017 Phase 4 Dexamethasone/Prednisolone;Cyclophosphamide;Vincristine;Daunorubicin;Asparaginase;G-CSF;Mercaptopurine;Cytarabine;Methotrexate;VP16;Vindesine;Adriamycin;Thioguanine;HDARAC;Cladribine
35 Multicenter Study to Optimise Therapy of B-ALL, Burkitt's NHL and High-Grade Non-Hodgkin's Lymphoma in Adults (Amend 7) Completed NCT00199082 Phase 4 Adriamycin;Cyclophosphamide;Cytarabine;Dexamethasone/Prednisolone;VP16;Ifosfamide;Methotrexate;G-CSF;Rituximab;Vincristine/Vindesine
36 Effect of Simvastatin on Sepsis and Febrile Neutropenia in Patients With Acute Lymphoblastic Leukemia Recruiting NCT05133310 Phase 4 Simvastatin
37 A Phase 4, Multi-center Open-label Feasibility Study to Evaluate Outpatient Blinatumomab Administration in Adult Subjects With Minimal Residual Disease (MRD) of B-precursor Acute Lymphoblastic Leukemia (ALL) in Complete Hematologic Remission Recruiting NCT04506086 Phase 4 Blinatumomab
38 Flumatinib Versus Imatinib Combined With Multiagent Chemotherapy for Newly Diagnosed Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia: A Prospective, Open-label，Randomized，Multi-center Clinical Trial Recruiting NCT05071482 Phase 4 Flumatinib;Imatinib
39 PROTOCOL FOR THE TREATMENT Acute Lymphoblastic Leukemia With Ph 'NEGATIVE IN ELDERLY PATIENTS (> 55 Years) Recruiting NCT01366898 Phase 4 Dexamethasona, Idarubicine, ARA-C, Methotrexate
40 Chemotherapy and Imatinib in Young Adults With Acute Lymphoblastic Leukemia Ph (BCR-ABL) POSITIVE Recruiting NCT01491763 Phase 4 Imatinib
41 Allogeneic Stem Cell Transplant for Children and Adolescents With Acute Lymoblastic Leukemia FORUM - Pharmacogenomic Study (add-on Study) Recruiting NCT02670564 Phase 4
42 Efficacy of the Use of Bortezomib for the Treatment of Relapsed Leukemia or Positive Minimal Residual Disease Recruiting NCT05137860 Phase 4 Bortezomib
43 Treatment Protocol For All Fragile Patients Ph' Negative Over 55 Years Recruiting NCT01358201 Phase 4 vINCRISTINE;Dexamethasone;Methotrexate;Cytosine arabinoside
44 Shanghai General Hospital, Shanghai, Jiao Tong University School of Medicine Recruiting NCT05379569 Phase 4 Fludarabine
45 A PHASE 4, OPEN-LABEL, RANDOMIZED STUDY OF TWO INOTUZUMAB OZOGAMICIN DOSE LEVELS IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA ELIGIBLE FOR HEMATOPOIETIC STEM CELL TRANSPLANTATION AND WHO HAVE RISK FACTOR(S) FOR VENO-OCCLUSIVE DISEASE Active, not recruiting NCT03677596 Phase 4 inotuzumab ozogamicin-dose level 2;Inotuzumab ozogamicin-dose level 1
46 Identification of New Immune Factors Specific of Relapse in Childhood B Lineage Acute Lymphoblastic Leukemia Terminated NCT02618109 Phase 4
47 ProphyALL - Pilot Study on Safety of Four Weekly Administrations of 7 mg/kg of Liposomal Amphotericin B (AmBisome®) in Antifungal Primary Prophylaxis Treatment of Elderly Patients With Acute Lymphoblastic Leukemia Undergoing Induction Chemotherapy Within the GMALL-Elderly Protocol Terminated NCT00386997 Phase 4 liposomal amphotericin B (AmBisome®)
48 Atomoxetine for Children With Acquired Attentional Disorders Following Completion of Chemotherapy for Acute Lymphocytic Leukemia Terminated NCT00299234 Phase 4 Atomoxetine
49 N-Acetylcysteine vs Placebo as Adjunctive Treatment in Pediatric Leukemia: A Single Blind, Randomized Controlled Trial Terminated NCT05611086 Phase 4 N-Acetylcysteine;Placebo
50 Pegylated Liposomal Doxorubicin-contained Versus Daunorubicin-contained VDCLD Regimen in Previously Untreated Adult Patients With Acute Lymphoblastic Leukemia: Complete Remission Rates and Changes of Leukemia Stem Cells Unknown status NCT02070523 Phase 3 VDCLD regimen

Search NIH Clinical Center for Leukemia, Acute Lymphoblastic

Inferred drug relations via UMLS 71 / NDF-RT 50 :


ASPARAGINASE
Cyclophosphamide
Idarubicin
Idarubicin Hydrochloride
Ifosfamide
mercaptopurine
pegaspargase
sargramostim

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Leukemia, Acute Lymphoblastic cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Leukemia, Acute Lymphoblastic:
Hemacord, umbilical cord blood-derived hematopoietic progenitor cells for hematopoietic reconstitution
Hematopoietic stem cells for treatment of hematologic malignancies
NiCord, umbilical cord blood-derived stem/progenitor cells for hemotological diseases
Umbilical cord-derived hematopoietic stem cells for treatment of acute lymphoblastic leukemia
Embryonic/Adult Cultured Cells Related to Leukemia, Acute Lymphoblastic:
Umbilical cord blood-derived hematopoietic progenitor cells (HEMACORD) PMIDs: 9828244
Bone marrow-derived hematopoietic stem cells
Umbilical cord blood-derived stem cells (NiCord) PMIDs: 22198152
Umbilical cord blood-derived hematopoietic stem cells (family) PMIDs: 17968329
Sources

Genetic Tests for Leukemia, Acute Lymphoblastic

About this section

Genetic tests related to Leukemia, Acute Lymphoblastic:

# Genetic test Affiliating Genes
1 Leukemia, Acute Lymphoblastic, Susceptibility to 28
2 B-Cell Acute Lymphoblastic Leukemia 28
Sources

Anatomical Context for Leukemia, Acute Lymphoblastic

About this section

Organs/tissues related to Leukemia, Acute Lymphoblastic:

MalaCards : Bone Marrow, T Cells, Bone, Spinal Cord, Myeloid, Liver, Spleen
ODiseA: Blood And Bone Marrow
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Leukemia, Acute Lymphoblastic:
# Tissue Anatomical CompartmentCell Relevance
1 Blood Hematopoietic Bone Marrow Hematopoietic Stem Cells Potential therapeutic candidate
2 Blood Peripheral Blood Mature B-Cells Affected by disease
3 Blood Hematopoietic Bone Marrow Small Pre B-Cells Affected by disease
Sources

Publications for Leukemia, Acute Lymphoblastic

About this section

Articles related to Leukemia, Acute Lymphoblastic:

(show top 50) (show all 38849)
# Title Authors PMID Year
1
FLT3 mutations in childhood acute lymphoblastic leukemia. 62 57 5
14670924 2004
2
First case of aplastic anemia in a Japanese child with a homozygous missense mutation in the NBS1 gene (I171V) associated with genomic instability. 53 62 5
15338273 2004
3
PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia. 62 5
30643249 2019
4
Leukaemia hijacks a neural mechanism to invade the central nervous system. 62 57
30022166 2018
5
Clonal evolution mechanisms in NT5C2 mutant-relapsed acute lymphoblastic leukaemia. 62 57
29342136 2018
6
Metabolic gatekeeper function of B-lymphoid transcription factors. 62 57
28192788 2017
7
Contrasting roles of histone 3 lysine 27 demethylases in acute lymphoblastic leukaemia. 62 57
25132549 2014
8
Loss of oncogenic Notch1 with resistance to a PI3K inhibitor in T-cell leukaemia. 62 57
25043004 2014
9
RAG-mediated recombination is the predominant driver of oncogenic rearrangement in ETV6-RUNX1 acute lymphoblastic leukemia. 62 57
24413735 2014
10
Global chromatin profiling reveals NSD2 mutations in pediatric acute lymphoblastic leukemia. 62 57
24076604 2013
11
Exome sequencing identifies mutation in CNOT3 and ribosomal genes RPL5 and RPL10 in T-cell acute lymphoblastic leukemia. 62 57
23263491 2013
12
Genetic inactivation of the polycomb repressive complex 2 in T cell acute lymphoblastic leukemia. 62 57
22237151 2012
13
The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. 62 57
22237106 2012
14
Oncogenic IL7R gain-of-function mutations in childhood T-cell acute lymphoblastic leukemia. 62 57
21892159 2011
15
BCL6 enables Ph+ acute lymphoblastic leukaemia cells to survive BCR-ABL1 kinase inhibition. 62 57
21593872 2011
16
CREBBP mutations in relapsed acute lymphoblastic leukaemia. 62 57
21390130 2011
17
Genetic variegation of clonal architecture and propagating cells in leukaemia. 62 57
21160474 2011
18
PHF6 mutations in T-cell acute lymphoblastic leukemia. 62 57
20228800 2010
19
Verification of the susceptibility loci on 7p12.2, 10q21.2, and 14q11.2 in precursor B-cell acute lymphoblastic leukemia of childhood. 62 57
20042726 2010
20
Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia. 62 57
19838194 2009
21
Loci on 7p12.2, 10q21.2 and 14q11.2 are associated with risk of childhood acute lymphoblastic leukemia. 62 57
19684604 2009
22
Germline genomic variants associated with childhood acute lymphoblastic leukemia. 62 57
19684603 2009
23
Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. 62 57
17344859 2007
24
Fusion of NUP214 to ABL1 on amplified episomes in T-cell acute lymphoblastic leukemia. 62 57
15361874 2004
25
Mutations in the Nijmegen Breakage Syndrome gene (NBS1) in childhood acute lymphoblastic leukemia (ALL). 62 5
11325820 2001
26
Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. 62 5
11290608 2001
27
Hematopoietic malignancies demonstrate loss-of-function mutations of BAX. 62 57
9531611 1998
28
A new fused transcript in Philadelphia chromosome positive acute lymphocytic leukaemia. 62 57
2825022 1987
29
A novel c-abl protein product in Philadelphia-positive acute lymphoblastic leukaemia. 62 57
3543692 1987
30
Unique forms of the abl tyrosine kinase distinguish Ph1-positive CML from Ph1-positive ALL. 62 57
3541203 1987
31
Measurable residual disease in acute lymphoblastic leukemia: methods and clinical context in adult patients. 62 41
36453516 2022
32
Histidine catabolism is a major determinant of methotrexate sensitivity. 57
29995852 2018
33
Germline De Novo Mutations in GNB1 Cause Severe Neurodevelopmental Disability, Hypotonia, and Seizures. 5
27108799 2016
34
Mutations in G protein β subunits promote transformation and kinase inhibitor resistance. 5
25485910 2015
35
Hypermethylation of specific microRNA genes in MLL-rearranged infant acute lymphoblastic leukemia: major matters at a micro scale. 62 46
21116279 2011
36
Gene silencing of MIR22 in acute lymphoblastic leukaemia involves histone modifications independent of promoter DNA methylation. 62 46
19807731 2010
37
Identification of new microRNA genes and aberrant microRNA profiles in childhood acute lymphoblastic leukemia. 62 46
18923441 2009
38
MicroRNA expression signatures accurately discriminate acute lymphoblastic leukemia from acute myeloid leukemia. 62 46
18056805 2007
39
Identification of novel FLT-3 Asp835 mutations in adult acute myeloid leukaemia. 5
11442493 2001
40
Sequence and analysis of the human ABL gene, the BCR gene, and regions involved in the Philadelphia chromosomal translocation. 57
7665185 1995
41
CARD11 mutation and HBZ expression induce lymphoproliferative disease and adult T-cell leukemia/lymphoma. 41
36446869 2022
42
Anti-spike antibody response to the COVID vaccine in lymphoma patients. 41
36454941 2022
43
Polymorphisms of the gamma-glutamyl hydrolase gene and risk of relapse to acute lymphoblastic leukemia in Mexico. 53 62
20197200 2010
44
Glucocorticoid receptor knock down reveals a similar apoptotic threshold but differing gene regulation patterns in T-cell and pre-B-cell acute lymphoblastic leukemia. 53 62
20170710 2010
45
Association between the methylenetetrahydrofolate reductase polymorphisms and risk of acute lymphoblastic leukemia in Serbian children. 53 62
20445408 2010
46
IL-7 receptor is expressed on adult pre-B-cell acute lymphoblastic leukemia and other B-cell derived neoplasms and correlates with expression of proliferation and survival markers. 53 62
20060740 2010
47
Simultaneous detection of MDR1 and WT1 gene expression to predict the prognosis of adult acute lymphoblastic leukemia. 53 62
20423567 2010
48
Genetic inactivation of Ikaros is a rare event in human T-ALL. 53 62
19796813 2010
49
STAT5 in B cell development and leukemia. 53 62
20227268 2010
50
Reversible posterior leukoencephalopathy syndrome in childhood: report of nine cases and review of the literature. 53 62
19809787 2010
Sources

Variations for Leukemia, Acute Lymphoblastic

About this section

ClinVar genetic disease variations for Leukemia, Acute Lymphoblastic:

5 (show all 42)
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 FLT3 NM_004119.3(FLT3):c.2504A>T (p.Asp835Val) SNV Pathogenic
 16272 rs121909646 GRCh37: 13:28592641-28592641
GRCh38: 13:28018504-28018504
2 FLT3 NM_004119.3(FLT3):c.2503G>T (p.Asp835Tyr) SNV Pathogenic
 16276 rs121913488 GRCh37: 13:28592642-28592642
GRCh38: 13:28018505-28018505
3 FLT3 NM_004119.3(FLT3):c.1777_1779del (p.Asp593del) DEL Pathogenic
 16278 rs587776834 GRCh37: 13:28608277-28608279
GRCh38: 13:28034140-28034142
4 ETV6 NM_001987.5(ETV6):c.1046T>C (p.Leu349Pro) SNV Pathogenic
 190241 rs786205155 GRCh37: 12:12037415-12037415
GRCh38: 12:11884481-11884481
5 GNB1 NM_002074.5(GNB1):c.239T>A (p.Ile80Asn) SNV Pathogenic
 224715 rs752746786 GRCh37: 1:1737942-1737942
GRCh38: 1:1806503-1806503
6 GNB1 NM_002074.5(GNB1):c.227A>G (p.Asp76Gly) SNV Pathogenic
 224711 rs869312821 GRCh37: 1:1737954-1737954
GRCh38: 1:1806515-1806515
7 NBN NM_002485.5(NBN):c.1903A>T (p.Lys635Ter) SNV Pathogenic
 142559 rs587782545 GRCh37: 8:90960063-90960063
GRCh38: 8:89947835-89947835
8 NBN NM_002485.5(NBN):c.1030C>T (p.Gln344Ter) SNV Pathogenic
 190229 rs767215758 GRCh37: 8:90971047-90971047
GRCh38: 8:89958819-89958819
9 PAX5 NM_016734.3(PAX5):c.239C>G (p.Pro80Arg) SNV Pathogenic
 624590 GRCh37: 9:37015165-37015165
GRCh38: 9:37015168-37015168
10 ETV6 NM_001987.4(ETV6):c.1153-5_1153-1del MICROSAT Pathogenic
 190240 GRCh37: 12:12038855-12038859
GRCh38: 12:11885921-11885925
11 NBN NM_002485.5(NBN):c.511A>G (p.Ile171Val) SNV Risk Factor
Uncertain Significance
 6946 rs61754966 GRCh37: 8:90990521-90990521
GRCh38: 8:89978293-89978293
12 NBN NM_002485.5(NBN):c.591_603delinsTTG (p.Pro198fs) INDEL Likely Pathogenic
 481871 rs1554564297 GRCh37: 8:90983500-90983512
GRCh38: 8:89971272-89971284
13 NBN NM_002485.5(NBN):c.897-2A>T SNV Likely Pathogenic
 219440 rs864622090 GRCh37: 8:90976737-90976737
GRCh38: 8:89964509-89964509
14 NBN NM_002485.5(NBN):c.156_157del (p.Ser53fs) DEL Likely Pathogenic
 371121 rs767454740 GRCh37: 8:90994964-90994965
GRCh38: 8:89982736-89982737
15 NBN NM_002485.5(NBN):c.2140C>T (p.Arg714Ter) SNV Likely Pathogenic
 182737 rs730881864 GRCh37: 8:90955525-90955525
GRCh38: 8:89943297-89943297
16 NBN NM_002485.5(NBN):c.2149A>T (p.Thr717Ser) SNV Uncertain Significance
 127865 rs587780093 GRCh37: 8:90955516-90955516
GRCh38: 8:89943288-89943288
17 NBN NM_002485.5(NBN):c.595C>T (p.Pro199Ser) SNV Uncertain Significance
 127874 rs587780097 GRCh37: 8:90983508-90983508
GRCh38: 8:89971280-89971280
18 NBN NM_002485.5(NBN):c.1262T>C (p.Leu421Ser) SNV Uncertain Significance
 127009 rs104895032 GRCh37: 8:90967646-90967646
GRCh38: 8:89955418-89955418
19 NBN NM_002485.5(NBN):c.425A>G (p.Asn142Ser) SNV Uncertain Significance
 127871 rs769414 GRCh37: 8:90993017-90993017
GRCh38: 8:89980789-89980789
20 NBN NM_002485.5(NBN):c.628G>T (p.Val210Phe) SNV Uncertain Significance
 127014 rs61754796 GRCh37: 8:90983475-90983475
GRCh38: 8:89971247-89971247
21 NBN NM_002485.5(NBN):c.1999T>C (p.Ser667Pro) SNV Uncertain Significance
 127863 rs587780091 GRCh37: 8:90958439-90958439
GRCh38: 8:89946211-89946211
22 NBN NM_002485.5(NBN):c.456G>A (p.Met152Ile) SNV Uncertain Significance
 127872 rs201816949 GRCh37: 8:90992986-90992986
GRCh38: 8:89980758-89980758
23 IKZF1 NM_006060.6(IKZF1):c.1047G>C (p.Gln349His) SNV Uncertain Significance
 1320280 GRCh37: 7:50467812-50467812
GRCh38: 7:50400114-50400114
24 IKZF1 NM_006060.6(IKZF1):c.1034G>A (p.Ser345Asn) SNV Uncertain Significance
 1327578 GRCh37: 7:50467799-50467799
GRCh38: 7:50400101-50400101
25 IKZF1 NM_006060.6(IKZF1):c.398T>C (p.Met133Thr) SNV Uncertain Significance
 1691526 GRCh37: 7:50444468-50444468
GRCh38: 7:50376770-50376770
26 IKZF1 NM_006060.6(IKZF1):c.1405G>C (p.Val469Leu) SNV Uncertain Significance
 1710943 GRCh37: 7:50468170-50468170
GRCh38: 7:50400472-50400472
27 IKZF1 NM_006060.6(IKZF1):c.1178G>C (p.Ser393Thr) SNV Uncertain Significance
 1710961 GRCh37: 7:50467943-50467943
GRCh38: 7:50400245-50400245
28 PAX5 NM_016734.3(PAX5):c.435G>C (p.Gln145His) SNV Uncertain Significance
 587563 rs758368747 GRCh37: 9:37006510-37006510
GRCh38: 9:37006513-37006513
29 HOXD4 NM_014621.3(HOXD4):c.242A>T (p.Glu81Val) SNV Uncertain Significance
 14888 rs104893636 GRCh37: 2:177016603-177016603
GRCh38: 2:176151875-176151875
30 NBN NM_002485.5(NBN):c.2215C>G (p.Leu739Val) SNV Uncertain Significance
 182730 rs370058152 GRCh37: 8:90949273-90949273
GRCh38: 8:89937045-89937045
31 NBN NM_002485.5(NBN):c.1034G>T (p.Gly345Val) SNV Uncertain Significance
 127852 rs587780089 GRCh37: 8:90971043-90971043
GRCh38: 8:89958815-89958815
32 NBN NM_002485.5(NBN):c.775G>A (p.Glu259Lys) SNV Uncertain Significance
 182716 rs201559159 GRCh37: 8:90982713-90982713
GRCh38: 8:89970485-89970485
33 NBN NM_002485.5(NBN):c.683T>G (p.Ile228Arg) SNV Uncertain Significance
 186350 rs777460725 GRCh37: 8:90983420-90983420
GRCh38: 8:89971192-89971192
34 NBN NM_002485.5(NBN):c.505C>T (p.Arg169Cys) SNV Uncertain Significance
 127873 rs182756889 GRCh37: 8:90990527-90990527
GRCh38: 8:89978299-89978299
35 NBN NM_002485.5(NBN):c.503G>A (p.Gly168Glu) SNV Uncertain Significance
 461570 rs1554566728 GRCh37: 8:90990529-90990529
GRCh38: 8:89978301-89978301
36 NBN NM_002485.5(NBN):c.431C>T (p.Thr144Ile) SNV Uncertain Significance
 485924 rs1554567906 GRCh37: 8:90993011-90993011
GRCh38: 8:89980783-89980783
37 NBN NM_002485.5(NBN):c.361G>C (p.Asp121His) SNV Uncertain Significance
 231708 rs777916019 GRCh37: 8:90993081-90993081
GRCh38: 8:89980853-89980853
38 NBN NM_002485.5(NBN):c.340G>T (p.Val114Phe) SNV Uncertain Significance
 219644 rs771034958 GRCh37: 8:90993102-90993102
GRCh38: 8:89980874-89980874
39 NBN NM_002485.5(NBN):c.119C>T (p.Ser40Leu) SNV Uncertain Significance
 141146 rs587781530 GRCh37: 8:90995002-90995002
GRCh38: 8:89982774-89982774
40 NBN NM_002485.5(NBN):c.11T>G (p.Leu4Arg) SNV Uncertain Significance
 461493 rs748090667 GRCh37: 8:90996779-90996779
GRCh38: 8:89984551-89984551
41 NBN NM_002485.5(NBN):c.390A>G (p.Gln130=) SNV Uncertain Significance
 625984 rs146150499 GRCh37: 8:90993052-90993052
GRCh38: 8:89980824-89980824
42 NBN NM_002485.5(NBN):c.260T>C (p.Phe87Ser) SNV Uncertain Significance
 187236 rs786203573 GRCh37: 8:90993663-90993663
GRCh38: 8:89981435-89981435

UniProtKB/Swiss-Prot genetic disease variations for Leukemia, Acute Lymphoblastic:

73
# Symbol AA change Variation ID SNP ID
1 PAX5 p.Gly183Ser VAR_070682 rs398123063

Copy number variations for Leukemia, Acute Lymphoblastic from CNVD:

6 (show top 50) (show all 2943)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 13316 1 1 117600000 Loss Acute lymphoblastic leukemia
2 13371 17 1 22200000 Deletion TP53 Acute lymphoblastic leukemia
3 13410 1 1 2300000 Copy number Acute lymphoblastic leukemia
4 13773 1 1 35400000 Duplication Acute lymphoblastic leukemia
5 13788 1 1 40300000 Duplication Acute lymphoblastic leukemia
6 13790 1 1 46500000 Gain Acute lymphoblastic leukemia
7 13836 12 10000000 12600000 Deletion ETV6 Acute lymphoblastic leukemia
8 13906 1 100818677 103024856 Loss DPH5 Acute lymphoblastic leukemia
9 13907 1 100818677 103024856 Loss EXTL2 Acute lymphoblastic leukemia
10 13908 1 100818677 103024856 Loss OLFM3 Acute lymphoblastic leukemia
11 13909 1 100818677 103024856 Loss S1PR1 Acute lymphoblastic leukemia
12 13910 1 100818677 103024856 Loss SLC30A7 Acute lymphoblastic leukemia
13 13911 1 100818677 103024856 Loss VCAM1 Acute lymphoblastic leukemia
14 13991 1 102370195 102561809 Deletion Acute lymphoblastic leukemia
15 14292 1 106673274 107678605 Loss NTNG1 Acute lymphoblastic leukemia
16 14293 1 106673274 107678605 Loss PRMT6 Acute lymphoblastic leukemia
17 14369 1 107716342 144004701 Loss ADAM30 Acute lymphoblastic leukemia
18 14370 1 107716342 144004701 Loss ADORA3 Acute lymphoblastic leukemia
19 14371 1 107716342 144004701 Loss AKR7A2P1 Acute lymphoblastic leukemia
20 14372 1 107716342 144004701 Loss AHCYL1 Acute lymphoblastic leukemia
21 14373 1 107716342 144004701 Loss AKNAD1 Acute lymphoblastic leukemia
22 14374 1 107716342 144004701 Loss ALX3 Acute lymphoblastic leukemia
23 14375 1 107716342 144004701 Loss AMIGO1 Acute lymphoblastic leukemia
24 14376 1 107716342 144004701 Loss AMPD1 Acute lymphoblastic leukemia
25 14377 1 107716342 144004701 Loss AMPD2 Acute lymphoblastic leukemia
26 14378 1 107716342 144004701 Loss AP4B1 Acute lymphoblastic leukemia
27 14379 1 107716342 144004701 Loss ATP1A1 Acute lymphoblastic leukemia
28 14380 1 107716342 144004701 Loss ATP5PB Acute lymphoblastic leukemia
29 14381 1 107716342 144004701 Loss ATXN7L2 Acute lymphoblastic leukemia
30 14382 1 107716342 144004701 Loss BCAS2 Acute lymphoblastic leukemia
31 14383 1 107716342 144004701 Loss BCL2L15 Acute lymphoblastic leukemia
32 14384 1 107716342 144004701 Loss LRIF1 Acute lymphoblastic leukemia
33 14385 1 107716342 144004701 Loss PFN1P2 Acute lymphoblastic leukemia
34 14386 1 107716342 144004701 Loss MAB21L3 Acute lymphoblastic leukemia
35 14387 1 107716342 144004701 Loss C1orf162 Acute lymphoblastic leukemia
36 14388 1 107716342 144004701 Loss INKA2 Acute lymphoblastic leukemia
37 15383 1 115048600 115061038 Copy number NRAS Acute lymphoblastic leukemia
38 15429 1 115400000 222100000 Gain Acute lymphoblastic leukemia
39 15832 1 119869201 120436800 Loss HMGCS2 Acute lymphoblastic leukemia
40 15833 1 119869201 120436800 Loss NBPF7P Acute lymphoblastic leukemia
41 15834 1 119869201 120436800 Loss NOTCH2 Acute lymphoblastic leukemia
42 15835 1 119869201 120436800 Loss PHGDH Acute lymphoblastic leukemia
43 15836 1 119869201 120436800 Loss REG4 Acute lymphoblastic leukemia
44 15837 1 119869201 120436800 Loss ZNF697 Acute lymphoblastic leukemia
45 15979 1 120700000 169100000 Loss CREG1 Acute lymphoblastic leukemia
46 16426 1 124300000 247249719 Deletion Acute lymphoblastic leukemia
47 16427 1 124300000 247249719 Duplication Acute lymphoblastic leukemia
48 16474 1 125000000 249250621 Copy number Acute lymphoblastic leukemia
49 16502 1 12600000 16100000 Deletion Acute lymphoblastic leukemia
50 16592 1 128000000 185104377 Copy number Acute lymphoblastic leukemia
Sources

Expression for Leukemia, Acute Lymphoblastic

About this section
Search GEO for disease gene expression data for Leukemia, Acute Lymphoblastic.
Sources

Pathways for Leukemia, Acute Lymphoblastic

About this section

Pathways related to Leukemia, Acute Lymphoblastic according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Cell differentiation - expanded index 74
Show member pathways
 11.33 MIR223 MIR203A MIR155
2
miRNAs involvement in the immune response in sepsis 74
11.12 MIR21 MIR203A MIR155
3
Interactions between immune cells and microRNAs in tumor microenvironment 74
10.81 MIR27A MIR21 MIR203A
4
miRNAs involved in DNA damage response 74
10.75 MIR27A MIR223 MIR21 MIR203A
5
Hematopoietic stem cell gene regulation by GABP alpha/beta complex 74
10.62 FLT3 ETV6
Sources

GO Terms for Leukemia, Acute Lymphoblastic

About this section

Cellular components related to Leukemia, Acute Lymphoblastic according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 RISC complex GO:0016442 9.53 MIR335 MIR27A MIR223 MIR21 MIR203A MIR155
2 extracellular vesicle GO:1903561 9.43 MIR27A MIR21 MIR152 MIR125A GNB1

Biological processes related to Leukemia, Acute Lymphoblastic according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of gene expression GO:0010629 9.55 MIR27A MIR21 MIR155 MIR125A CDKN2B-AS1
2 miRNA-mediated gene silencing GO:0035195 9.44 MIR335 MIR27A MIR223 MIR21 MIR203A MIR155
3 negative regulation of cytokine-mediated signaling pathway GO:0001960 9.26 MIR125A MIR21
4 negative regulation of interleukin-1-mediated signaling pathway GO:2000660 8.96 MIR27A MIR21

Molecular functions related to Leukemia, Acute Lymphoblastic according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA 3'-UTR binding GO:0003730 9.5 MIR335 MIR27A MIR223 MIR21 MIR155 MIR152
2 mRNA base-pairing translational repressor activity GO:1903231 9.23 MIR335 MIR27A MIR223 MIR21 MIR203A MIR155
Sources

Sources for Leukemia, Acute Lymphoblastic

About this section
2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....